UCB and Amgen not to progress development of romosozumab for fracture healing

13 February 2013

Belgium’s leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq: AMGN) have decided to not pursue a Phase III clinical trial program for CDP7851/AMG785 (romosozumab) in acceleration of fracture healing based on the evaluation of currently available Phase II results from accelerated fracture healing studies and general regulatory guidance on fracture healing programs.

However, the safety profile of this program remains consistent with what has been seen in the post-menopausal osteoporosis program and is not a factor in this decision to not pursue acceleration of fracture healing.

UCB's US shares dropped 3.9% to $27.60 in afternoon trading, while Amgen stock dipped 1.4% to $85.09 on the news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK